225Ac-PSMA617: PSMA targeting alpha-radiation therapy of patients with mCRPC

To evaluate the potential of PSMA targeting 225Ac-PSMA617 as a promising new treatment option for poor prognosis advanced stage mCRPC (metastatic castration-resistant prostate cancer) patients. An appropriate starting activity for clinical application of 225Ac-PSMA617 was defined by preliminary dosimetry modeling. The treatment protocol was further refined by an empirical dose escalation during “compassionate use” in a first group of advanced stage patients. The derived “standard operation procedure” was used to treat a larger group of patients, which now has >6 months of follow up. Here we report our clinical observations in regard to anti-tumor activity as well as acute and mid-term toxicities experienced with this new concept of mCRPC therapy.

KRATOCHWIL Clemens;  BRUCHERTSEIFER Frank;  GIESEL Frederik;  APOSTOLIDIS Christos;  HABERKORN Uwe;  MORGENSTERN Alfred; 

2017-08-01

European Commission - Joint Research Centre

JRC106148

http://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/,    https://publications.jrc.ec.europa.eu/repository/handle/JRC106148,